Related Experiment Videos
Estrogen receptor mutations in human disease.
Matthew H Herynk1, Suzanne A W Fuqua
1Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA.
Endocrine Reviews
|December 8, 2004
Summary
Estrogen receptors (ERalpha and ERbeta) play a role in breast cancer. Research has identified numerous splice variants and a few mutations in these receptors, impacting their function.
Area of Science:
- Endocrinology
- Molecular Biology
- Oncology
Background:
- Estrogen's role in breast cancer development has been recognized since the 1800s.
- Estrogen receptors (ERalpha and ERbeta) were identified and cloned in the late 20th century.
- Research has focused on understanding ER alterations in various diseases.
Purpose of the Study:
- To review alterations in ERalpha and ERbeta in the context of breast cancer.
- To summarize findings on naturally occurring splice variants and point mutations.
- To discuss the use of experimental mutagenesis in studying ER function.
Main Methods:
- Literature review of studies on ERalpha and ERbeta.
- Analysis of identified splice variants and point mutations in clinical samples.
- Examination of experimental mutagenesis data for ER function.
Main Results:
- Numerous splice variants of ERalpha and ERbeta have been identified in normal and cancerous tissues.
- Only a limited number of point mutations in ERs have been found in human patients.
- Experimental mutagenesis is employed to understand the functional impact of ER alterations.
Conclusions:
- ERalpha and ERbeta alterations, particularly splice variants, are prevalent in breast cancer.
- Understanding these alterations is crucial for elucidating ER-mediated mechanisms in cancer.
- Further research is needed to fully characterize the functional consequences of ER mutations and variants.